Loading...
Phathom Pharmaceuticals, Inc.
PHAT•NASDAQ
HealthcareBiotechnology
$8.92
$4.23(90.19%)
Phathom Pharmaceuticals, Inc. (PHAT) Financial Performance & Statements
Review Phathom Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
8001.47%
↑ 8001.47%
Operating Income Growth
-65.84%
↓ 65.84%
Net Income Growth
-65.84%
↓ 65.84%
Operating Cash Flow Growth
-93.90%
↓ 93.90%
Operating Margin
-349.84%
↓ 349.84%
Gross Margin
86.23%
↑ 86.23%
Net Profit Margin
-307.20%
↓ 307.20%
ROE
99.31%
↑ 99.31%
ROIC
-130.07%
↓ 130.07%
Phathom Pharmaceuticals, Inc. (PHAT) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Phathom Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $29.66M | $16.35M | $7.32M | $1.91M |
| Cost of Revenue | $3.81M | $2.36M | $1.38M | $426000.00 |
| Gross Profit | $25.85M | $14.00M | $5.95M | $1.49M |
| Gross Profit Ratio | $0.87 | $0.86 | $0.81 | $0.78 |
| R&D Expenses | $8.58M | $8.69M | $7.38M | $9.43M |
| SG&A Expenses | $76.68M | $76.10M | $75.87M | $62.01M |
| Operating Expenses | $85.27M | $84.79M | $83.25M | $71.44M |
| Total Costs & Expenses | $89.08M | $87.15M | $84.62M | $71.87M |
| Interest Income | $3.51M | $3.71M | $3.62M | $4.31M |
| Interest Expense | $18.59M | $18.48M | $17.76M | $17.17M |
| Depreciation & Amortization | $193000.00 | $191000.00 | $197000.00 | $214000.00 |
| EBITDA | -$55.66M | -$66.90M | -$73.48M | -$65.47M |
| EBITDA Ratio | -$1.88 | -$4.09 | -$10.03 | -$34.24 |
| Operating Income | -$59.42M | -$70.80M | -$77.30M | -$69.95M |
| Operating Income Ratio | -$2.003 | -$4.33 | -$10.55 | -$36.59 |
| Other Income/Expenses (Net) | -$15.03M | -$14.78M | -$14.15M | -$12.90M |
| Income Before Tax | -$74.45M | -$85.58M | -$91.45M | -$82.85M |
| Income Before Tax Ratio | -$2.51 | -$5.23 | -$12.49 | -$43.33 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $170724.00 |
| Net Income | -$74.45M | -$85.58M | -$91.45M | -$82.85M |
| Net Income Ratio | -$2.51 | -$5.23 | -$12.49 | -$43.33 |
| EPS | -$1.05 | -$1.32 | -$1.56 | -$1.42 |
| Diluted EPS | -$1.05 | -$1.32 | -$1.56 | -$1.42 |
| Weighted Avg Shares Outstanding | $71.04M | $64.63M | $58.56M | $58.37M |
| Weighted Avg Shares Outstanding (Diluted) | $71.04M | $64.63M | $58.56M | $58.37M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan